Type 2 DiabetesPREPT2DNCT04208230
Progression and Etiology of Cortical Porosity in Diabetic Bone Disease
An observational study of Type 2 Diabetes, run by University of California, San Francisco at 1 site in United States.
Trial summary
Type 2 diabetes is associated with increased cortical bone porosity and increased fracture risk. The goal of this proposed study is to understand the longitudinal evolution of cortical bone porosity and to investigate the underlying biological processes that drive increased cortical porosity and fracture risk in the… Read more about this study
- Who is it for?
- Ages 50 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- XtremeCT
- Type of treatment
- Medical device
- How many people
- 96 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Jan 2017to 15 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects with type 2 diabetes will be recruited from primary care clinics all over San Francisco;
Who may be able to join
- Postmenopausal female and/or male
- 50-70 years old
- Body mass index (BMI) of 18-40
- Subjects with bone mineral density of: 0 ≥ T-score > -2.5
- Additional requirement for type II diabetes patients:
- Patients has a history of type II diabetes, as defined by the American Diabetes Association for more than 3 years. Patients must either have a documented HbA1C of 6.5 or higher for 3 or more years if they are not undergoing pharmacological treatment (diet controlled), or must have been receiving pharmacological treatment for the past 3 years.
Who cannot join
- Perimenopausal women, defined as last menses within previous 3 years
- History of metabolic bone disease other than post-menopausal bone loss. Persons with the following diseases: chronic gastrointestinal disease (including inflammatory bowel disease, celiac disease, or other malabsorptive disease including short-gut syndrome), renal or hepatic impairment (known cirrhosis or if transaminase levels 3 times the upper limit of normal)
- Current alcohol consumption (>3 alcohol drinks/day), current illicit drug use.
- Use of medications known to impact bone and mineral metabolism, including use of a bisphosphonate or teriparatide in the last year or for >12 months ever, current calcitonin, prednisone > 5mg daily or the equivalent glucocorticoid for > 10 days in the last 3 months, current thiazolidinedione (TZD), thyroid hormone replacement with current thyroid stimulating hormone < 0.1 miu/L. Patients undergoing hormone/testosterone replacement will NOT be excluded meaning they can be enrolled)
- Trauma or surgery near radius or tibia imaging sites
- An episode of immobilization lasting longer than 1 week in the previous 6 months
Show all 9Show fewer
- Estimated Glomerular Filtration Rate (eGFR)< 50 mL/min/1.73 m2 (baseline) or < 40 (follow-up). The investigators will require eGFR ≥ 50 at baseline in an effort to avoid the possibility of an enrolled subject dropping below the established safety level of 40 at follow-up. This was determined knowing that eGFR can decline at a rate of approximately 4.0 per year in diabetics (much lower in non-diabetics).
- Conditions excluded by x-ray or MRI safety guidelines
- Body mass index greater than 40 as these subjects will be too large to fit into the gantry of the MR scanner or exceed weight limitations of the MR table
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California San Francisco
San Francisco, California, 94197
About this study
Type 2 diabetes is associated with increased cortical bone porosity and increased fracture risk. The goal of this proposed study is to understand the longitudinal evolution of cortical bone porosity and to investigate the underlying biological processes that drive increased cortical porosity and fracture risk in the setting of diabetes. The investigators will apply novel techniques for in vivo imaging of cortical pores to patients with type 2 diabetes and controls in a longitudinal prospective study. This work will establish the longitudinal progression of cortical porosity and determine whether pore content can serve as a predictor of future cortical degradation and bone fragility.
Read the detailed description
The overall goal of this proposed study is to investigate the underlying biological processes that drive increased cortical porosity in the setting of Type 2 Diabetes and to understand the longitudinal evolution of human diabetic bone disease with a special focus on cortical porosity. The investigators propose the first longitudinal study of pore progression in T2D patients, which will be performed using a novel combined high-resolution peripheral quantitative computed tomography (HR-pQCT) and contrast enhanced magnetic resonance (CE MR) imaging approach. The investigators will use novel image analysis approaches to characterize pore content and spatial distribution of porosity within the cortex, and micro finite element (μFE) analysis to quantify biomechanical impact of porosity.
Bone quality deficits underlying increased fragility in T2D are not fully understood. At the tissue level, research evaluating deficits in material properties and fracture resistance is ongoing. At the structural level, increased cortical porosity is a clearly established deficit in bone quality in T2D. Porosity is a major determinant of strength, stiffness, and fracture toughness of cortical tissue, and therefore represents an important target for the prevention or reversal of T2D-associated skeletal fragility.
The mechanisms driving increased cortical porosity in T2D are unknown. To develop treatments specifically targeted at the prevention or reversal of pathological porosity, the investigators must understand the biological drivers of porosity. Today these biological drivers are unknown. Within the compact cortex, formation of large cortical pores has been attributed to clustering of osteons and merging of Haversian canals. At the endocortical border, 'trabecularization' or marrow space expansion is hypothesized to drive observed increases in cortical porosity. Multiple mechanisms of pore space expansion likely are at play in diabetic bone disease.
Increased marrow adiposity and compromised microvascular health are recognized aspects of T2D mellitus, and may be implicated in the development of pathological porosity. Studies investigating rodent models and humans have established the association of increased marrow fat with T2D. (BMI alone, in contrast, has not been shown to have an association with marrow fat.) Increased marrow fat - in turn - is associated with low Bone Mineral Density (BMD) and poor trabecular microstructure. The investigators have also documented that increased marrow fat is associated with vertebral fracture, independent of BMD. The historic concept of marrow fat as merely a passive filler has been superseded by an appreciation for this fat depot as a dynamic player in bone quality. To date this link has been studied primarily in terms of trabecular bone microstructure; the investigators propose that it could be a player in cortical bone microstructure as well. Microvascular complications of T2D are among the most serious manifestations of the disease. In advanced disease, neovascularization through the process of angiogenesis leads to progression of retinopathy and nephropathy. Recent work has suggested that microvascular pathology also affects trabecular bone quality in diabetes. In cortical bone, where the majority of porosity contains blood vessels, neovascularization necessitates removal of bone tissue. Therefore the investigators hypothesize that microvascular pathology may be influencing cortical microstructural changes in T2D.
Content of pathological pore space may indicate drivers of pore space expansion, and lead to strategies for predicting and preventing porosity-related fractures. Characterization of pore content may indicate pore space enlargement by expansion of the marrow cavity, expansion of the vascular network, or both. If the investigators discover that altered marrow distribution or composition is associated with increased porosity in T2D, this suggests that expansion of the marrow cavity may be contributing to pathological porosity. In this case the investigators would direct future efforts towards the emerging topic of fat-bone interactions, specifically: 1) the balance between osteoblast and adipocyte differentiation occurring from a common multipotent precursor; and 2) the action of adipokines on bone remodeling. If the investigators determine that altered vessel distribution or microvascular health is associated with increased porosity in T2D, this suggests that the vascular network may be contributing to pathological porosity. In this case the investigators would direct future research toward the interaction between the vascular system and cortical bone remodeling. The vascular system is known to influence bone remodeling through vasoactive substances released by endothelial cells. In the context of disuse, for example, bone loss is associated with increased vascularity and hyperemia, achieved by the release of vasoactive substances by endothelial cells. As the investigators look at these possible mechanisms of increased cortical porosity, appropriate treatment strategies will be clarified. Specifically, increased porosity related to fat metabolism might indicate interventions focused on directing mesenchymal stem cell differentiation towards osteoblastogenesis or regulating adipokine action on bone remodeling. Alternatively, increased porosity due to microvascular damage might indicate modulation of vasoregulators or anti-angiogenic therapy as used to combat neovascularization and bone erosion in rheumatoid arthritis.
- Conditions
- Type 2 Diabetes
- Being tested
- XtremeCT
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
XtremeCTDevice
Also called High-resolution peripheral quantitative computed tomography (HRpQCT)
HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
| Study group | Role | What they receive |
|---|---|---|
| Subjects diagnosed with type 2 diabetes mellitus | Subjects with type 2 diabetes defined as those with (1) history and diagnosis of T2D and pharmacologic treatment for a minimum of 3 years OR (2) history and diagnosis of T2D with documented HgbA1C of 6.5 or higher for a minimum of 3 years if they are not under pharmacologic treatment (i.e., diet-controlled) Receives: Device: XtremeCT | |
| Control | Non-diabetic control group. These subjects must not have pre-diabetes. Receives: Device: XtremeCT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amount of fat within cortical pores at the distal tibia at baseline
The investigators will apply a combined HR-pQCT and MR pore content characterization technique to quantify the amount of fat within cortical pores at the distal tibia in T2D subjects and matched controls.
Measured: Baseline
Amount of vessels within cortical pores at the distal tibia at baseline.
The investigators will apply a combined HRpQCT and MR pore content characterization technique to quantify the proportion of cortical pores containing vessels at the distal tibia at baseline in T2D subjects and matched controls. .
Measured: Baseline
Association between Type 2 diabetes status and marrow fat at the distal tibia
Cortical porosity at the distal tibia will be assessed by HRpQCT at baseline and 24 months in T2D subjects and matched controls.
Measured: Baseline and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2019
- Study start3 Jan 2017
- Primary completion31 Dec 2022
- Study completion15 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Galateia Kazakia, PhD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04208230
- Sponsor's protocol ID
- iRIS 16-20196
- Acronym
- PREPT2D
- Status last verified
- Nov 2023
- First submitted
- 19 Dec 2019
- Last updated
- 18 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Progression and Etiology of Cortical Porosity in Diabetic Bone Disease
- ClinicalTrials.gov ID
- NCT04208230
- Acronym / sponsor ID
- PREPT2D / iRIS 16-20196
- Conditions
- Type 2 Diabetes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 96 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 3 Jan 2017 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 15 Nov 2023 (actual)
- First posted
- 23 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 2 diabetes is associated with increased cortical bone porosity and increased fracture risk. The goal of this proposed study is to understand the longitudinal evolution of cortical bone porosity and to investigate the underlying biological processes that drive increased cortical porosity and fracture risk in the setting of diabetes. The investigators will apply novel techniques for in vivo imaging of cortical pores to patients with type 2 diabetes and controls in a longitudinal prospective study. This work will establish the longitudinal progression of cortical porosity and determine whether pore content can serve as a predictor of future cortical degradation and bone fragility.
Detailed description
The overall goal of this proposed study is to investigate the underlying biological processes that drive increased cortical porosity in the setting of Type 2 Diabetes and to understand the longitudinal evolution of human diabetic bone disease with a special focus on cortical porosity. The investigators propose the first longitudinal study of pore progression in T2D patients, which will be performed using a novel combined high-resolution peripheral quantitative computed tomography (HR-pQCT) and contrast enhanced magnetic resonance (CE MR) imaging approach. The investigators will use novel image analysis approaches to characterize pore content and spatial distribution of porosity within the cortex, and micro finite element (μFE) analysis to quantify biomechanical impact of porosity.
Bone quality deficits underlying increased fragility in T2D are not fully understood. At the tissue level, research evaluating deficits in material properties and fracture resistance is ongoing. At the structural level, increased cortical porosity is a clearly established deficit in bone quality in T2D. Porosity is a major determinant of strength, stiffness, and fracture toughness of cortical tissue, and therefore represents an important target for the prevention or reversal of T2D-associated skeletal fragility.
The mechanisms driving increased cortical porosity in T2D are unknown. To develop treatments specifically targeted at the prevention or reversal of pathological porosity, the investigators must understand the biological drivers of porosity. Today these biological drivers are unknown. Within the compact cortex, formation of large cortical pores has been attributed to clustering of osteons and merging of Haversian canals. At the endocortical border, 'trabecularization' or marrow space expansion is hypothesized to drive observed increases in cortical porosity. Multiple mechanisms of pore space expansion likely are at play in diabetic bone disease.
Increased marrow adiposity and compromised microvascular health are recognized aspects of T2D mellitus, and may be implicated in the development of pathological porosity. Studies investigating rodent models and humans have established the association of increased marrow fat with T2D. (BMI alone, in contrast, has not been shown to have an association with marrow fat.) Increased marrow fat - in turn - is associated with low Bone Mineral Density (BMD) and poor trabecular microstructure. The investigators have also documented that increased marrow fat is associated with vertebral fracture, independent of BMD. The historic concept of marrow fat as merely a passive filler has been superseded by an appreciation for this fat depot as a dynamic player in bone quality. To date this link has been studied primarily in terms of trabecular bone microstructure; the investigators propose that it could be a player in cortical bone microstructure as well. Microvascular complications of T2D are among the most serious manifestations of the disease. In advanced disease, neovascularization through the process of angiogenesis leads to progression of retinopathy and nephropathy. Recent work has suggested that microvascular pathology also affects trabecular bone quality in diabetes. In cortical bone, where the majority of porosity contains blood vessels, neovascularization necessitates removal of bone tissue. Therefore the investigators hypothesize that microvascular pathology may be influencing cortical microstructural changes in T2D.
Content of pathological pore space may indicate drivers of pore space expansion, and lead to strategies for predicting and preventing porosity-related fractures. Characterization of pore content may indicate pore space enlargement by expansion of the marrow cavity, expansion of the vascular network, or both. If the investigators discover that altered marrow distribution or composition is associated with increased porosity in T2D, this suggests that expansion of the marrow cavity may be contributing to pathological porosity. In this case the investigators would direct future efforts towards the emerging topic of fat-bone interactions, specifically: 1) the balance between osteoblast and adipocyte differentiation occurring from a common multipotent precursor; and 2) the action of adipokines on bone remodeling. If the investigators determine that altered vessel distribution or microvascular health is associated with increased porosity in T2D, this suggests that the vascular network may be contributing to pathological porosity. In this case the investigators would direct future research toward the interaction between the vascular system and cortical bone remodeling. The vascular system is known to influence bone remodeling through vasoactive substances released by endothelial cells. In the context of disuse, for example, bone loss is associated with increased vascularity and hyperemia, achieved by the release of vasoactive substances by endothelial cells. As the investigators look at these possible mechanisms of increased cortical porosity, appropriate treatment strategies will be clarified. Specifically, increased porosity related to fat metabolism might indicate interventions focused on directing mesenchymal stem cell differentiation towards osteoblastogenesis or regulating adipokine action on bone remodeling. Alternatively, increased porosity due to microvascular damage might indicate modulation of vasoregulators or anti-angiogenic therapy as used to combat neovascularization and bone erosion in rheumatoid arthritis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Subjects diagnosed with type 2 diabetes mellitus | – | Device: XtremeCTSubjects with type 2 diabetes defined as those with (1) history and diagnosis of T2D and pharmacologic treatment for a minimum of 3 years OR (2) history and diagnosis of T2D with documented HgbA1C of 6.5 or higher for a minimum of 3 years if they are not under pharmacologic treatment (i.e., diet-controlled) |
| Control | – | Device: XtremeCTNon-diabetic control group. These subjects must not have pre-diabetes. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects with type 2 diabetes will be recruited from primary care clinics all over San Francisco;
Key inclusion criteria (6 listed)
- Postmenopausal female and/or male
- 50-70 years old
- Body mass index (BMI) of 18-40
- Subjects with bone mineral density of: 0 ≥ T-score > -2.5
- Additional requirement for type II diabetes patients:
Key exclusion criteria (9 listed)
- Perimenopausal women, defined as last menses within previous 3 years
- History of metabolic bone disease other than post-menopausal bone loss. Persons with the following diseases: chronic gastrointestinal disease (including inflammatory bowel disease, celiac disease, or other malabsorptive disease including short-gut syndrome), renal or hepatic impairment (known cirrhosis or if transaminase levels 3 times the upper limit of normal)
- Current alcohol consumption (>3 alcohol drinks/day), current illicit drug use.
- Use of medications known to impact bone and mineral metabolism, including use of a bisphosphonate or teriparatide in the last year or for >12 months ever, current calcitonin, prednisone > 5mg daily or the equivalent glucocorticoid for > 10 days in the last 3 months, current thiazolidinedione (TZD), thyroid hormone replacement with current thyroid stimulating hormone < 0.1 miu/L. Patients undergoing hormone/testosterone replacement will NOT be excluded meaning they can be enrolled)
- Trauma or surgery near radius or tibia imaging sites
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| XtremeCTAlso: High-resolution peripheral quantitative computed tomography (HRpQCT)HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner. | Device | Control, Subjects diagnosed with type 2 diabetes mellitus |
Primary outcome
Amount of fat within cortical pores at the distal tibia at baseline
Time frame: Baseline
The investigators will apply a combined HR-pQCT and MR pore content characterization technique to quantify the amount of fat within cortical pores at the distal tibia in T2D subjects and matched controls.
Amount of vessels within cortical pores at the distal tibia at baseline.
Time frame: Baseline
The investigators will apply a combined HRpQCT and MR pore content characterization technique to quantify the proportion of cortical pores containing vessels at the distal tibia at baseline in T2D subjects and matched controls. .
Association between Type 2 diabetes status and marrow fat at the distal tibia
Time frame: Baseline and 24 months
Cortical porosity at the distal tibia will be assessed by HRpQCT at baseline and 24 months in T2D subjects and matched controls.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Galateia Kazakia, PhD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amount of fat within cortical pores at the distal tibia at baseline (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.